Chilton Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Chilton Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,000	Closed	-$118K	–	392
2022 Q2	$118K	Buy	+1,000	New	+$119K	0.01%	252
2014 Q1	–	Sell	-180	Closed	-$13.6K	–	218
2013 Q4	$13.6K	Hold	180	–	–	﹤0.01%	310
2013 Q3	$12.6K	Buy	+180	New	+$11.8K	﹤0.01%	318

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Chilton Capital Management's IBB Position: Q3 2022 in Review

Chilton Capital Management sold out of iShares Biotechnology ETF (IBB) in Q3 2022, closing a stake of 1,000 shares — an estimated $118K sold.

Chilton Capital Management first reported a position in IBB in Q3 2013 and held it in 3 quarters. The position peaked at $118K in Q2 2022. 829 funds tracked by Wall St. Rank hold IBB as of Q3 2022.

Chilton Capital Management reported no remaining iShares Biotechnology ETF position as of Q3 2022 after selling out during the quarter.
Chilton Capital Management sold 1,000 iShares Biotechnology ETF shares in Q3 2022, an estimated $118K.
Chilton Capital Management first reported a position in iShares Biotechnology ETF in Q3 2013 and held it in 3 quarters.
Chilton Capital Management's iShares Biotechnology ETF position peaked at $118K in Q2 2022.
829 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2022.

Based on Chilton Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.